Quick Facts: Therapeutic Areas

• Addresses: Symptoms associated with nocturnal heartburn.
• Context: Used for managing gastroesophageal reflux disease (GERD).
• Role: Employed when other nonpharmacologic measures or agents have not provided adequate symptom relief.

---

What Propulsid Treats: Main Uses and Benefits

The agent Propulsid (cisapride) is designated for the symptomatic management of adults who experience nocturnal heartburn related to gastroesophageal reflux disease (GERD). This medication is an option when lifestyle changes and other therapeutic agents have not supported sufficient relief.

The use of Propulsid is associated with supporting the movement of stomach contents. This action can help in reducing the occurrence of acid reflux into the esophagus during nighttime hours. The medication's role is to facilitate a reduction in symptoms for specific patient populations. Due to safety considerations, its use is typically reserved for cases where other treatments are considered inadequate, following a comprehensive risk-benefit assessment.

The eligibility for Propulsid (cisapride) is defined by stringent regulatory restrictions, primarily due to the risk of serious cardiac arrhythmias. Its use is largely confined to adults who suffer from severe nocturnal heartburn due to gastroesophageal reflux disease (GERD) and have failed all other standard treatments. In the U.S., access is limited to a formal Limited Access Program for specific patients with no alternatives.

Eligibility Scope

Category	Official Regulatory Statement
Populations for whom use is allowed	Adults for refractory nocturnal GERD symptoms; Patients enrolled in the Limited Access Program.
Populations for whom use is contraindicated	Patients with pre-existing heart conditions, including a prolonged QTc interval, congenital Long QT Syndrome, structural heart defects, or congestive heart failure [Source 1.1, 1.6].
Age-related eligibility rules	Children younger than 16 years are excluded, as safety and effectiveness have not been demonstrated for any use [Source 1.2].
Condition-specific eligibility rules	Contraindicated in patients with renal failure, respiratory failure, uncorrected electrolyte disorders, or conditions risking gastrointestinal hemorrhage, obstruction, or perforation [Source 1.1, 1.5].

Connection to the overall eligibility profile

The regulatory profile dictates that use is strictly defined by the absence of these severe risk factors, classifying large patient populations as formally contraindicated. The medicine is formally labeled for use in adults only under controlled, limited conditions, with its status reflecting a severe cardiac risk profile.

Interactions with other medicines and products

The interaction profile of Propulsid (cisapride) is primarily defined by high-level restrictions related to metabolism and cardiac rhythm.

Formal Contraindicated Combinations

Co-administration with several medicinal product classes is formally prohibited due to two principal regulatory concerns:

• Potent CYP3A4 Inhibitors: Co-use with potent inhibitors of the Cytochrome P450 3A4 (CYP3A4) enzyme is contraindicated. This mechanism prevents the clearance of cisapride, leading to significantly increased plasma concentrations and heightened risk of serious adverse cardiac events. Prohibited medicines include oral and intravenous Azole Antifungals (e.g., Ketoconazole), Macrolide Antibiotics (e.g., Erythromycin), and HIV Protease Inhibitors (e.g., Indinavir).
• QTc-Prolonging Drugs: Co-administration with any medication known to prolong the cardiac QTc interval is contraindicated due to an additive pharmacodynamic effect. This increases the risk of ventricular arrhythmias, such as Torsades de Pointes. Prohibited agents include certain antiarrhythmics (e.g., Quinidine) and Sparfloxacin.

Food and Substance Restrictions

Consumption of Grapefruit Juice is prohibited because it inhibits CYP3A4, causing elevated cisapride exposure. The regulatory profile also notes that cisapride enhances the sedative effects of alcohol.

Other Documented Interactions

Co-administration with Cimetidine is documented to increase cisapride plasma levels by inhibiting its metabolism, while Ranitidine has been documented to have no such effect. Anticholinergic drugs may counteract or reduce the prokinetic effect of cisapride.

The drug Propulsid (cisapride) is a prokinetic agent that primarily modulates motility within the gastrointestinal tract. Its mechanism of action involves highly specific modulation of neurotransmitter signaling pathways to regulate muscle contractions and coordinated movement.

Modulating Motility via 5- HT4 Receptor Agonism

This domain covers the drug's core action as a selective 5- HT4 receptor agonist. Propulsid binds to and activates the 5- HT4 receptors located on the presynaptic terminals of the intrinsic primary afferent neurons (IPANs) within the myenteric plexus. This activation leads to the release of acetylcholine (ACh), a key excitatory neurotransmitter, which subsequently induces coordinated contraction of gastrointestinal smooth muscle, establishing the directionality of peristalsis.

Augmenting Cholinergic Neurotransmission Cascades

The increased release of acetylcholine due to 5- HT4 agonism results in a stronger signal across the neuromuscular junction, modifying early molecular steps that shape systemic physiological outcomes. This focused augmentation of the natural cholinergic cascade modifies the effects of increased mediator activity, contributing to the regulation of previously heightened physiological responses through modified contractile parameters and resulting in measurable adjustments to physiological motor functions.

Instruction Map: How to use Propulsid — Official Administration Guidelines

---

The usage of Propulsid (cisapride) is defined by a precise, structured, and strictly monitored administration protocol.

Administration Scope

Instruction	Detail
Route of administration	Oral only, using the available tablets or oral suspension forms.
Dosing schedule	Therapy is typically initiated with 10 mg per dose. The dosage may be increased up to 20 mg per dose if needed, but the minimum effective dose must be used and should not be exceeded.
Timing in relation to meals (if applicable)	Doses are administered four times daily (QID), taken at least 15 minutes before meals and the final dose taken at bedtime. Grapefruit juice must be avoided during therapy.
Preparation requirements (if applicable)	The liquid form is administered as supplied, with avoidance of grapefruit juice being a key constraint.
Age-group administration rules	Hepatic Impairment: The total daily dose must be halved for individuals with known hepatic insufficiency. Older Adults: Doses are similar to younger adults, but careful monitoring is advised.
Missed-dose rules	If a dose is missed, the patient should skip the missed dose and resume the next regularly scheduled dose; do not take a double dose.
Special procedural conditions	Prior to initiation, a baseline 12-lead ECG and assessment of serum electrolytes (potassium, calcium, and magnesium) and creatinine are required. Use is restricted to an investigational limited access program.

---

Instruction Classifications (High-Level)

Classification	Detail
Administration method type	Oral
Frequency pattern	Four times daily (QID)
Use-context constraints	Limited access and mandated pre-initiation cardiac/electrolyte screening.

---

Resulting Procedural Structure

Official step sequence:

• Complete required pre-initiation screening, including ECG and electrolyte testing.
• Administer the medicine orally (tablet or suspension) at the starting dosage of 10 mg per dose.
• Take the four daily doses 15 minutes before meals and at bedtime.
• Adjust the daily dose by halving the total amount for patients with hepatic impairment.
• Discontinue the medicine if the intended result is not achieved.

Connection to the overall use protocol: The official usage protocol dictates a precise, structured, and strictly monitored administration pattern. It defines the exact oral route, four-times-daily frequency, and specific timing relative to meals required for its administration. This framework also includes mandatory procedural steps for initiation and specific dose adjustments for hepatic impairment.

Research Evidence / Overview of Studies for Propulsid

The research evidence for Propulsid (cisapride) is built upon controlled clinical trials and physiological studies that have examined its effects on upper gastrointestinal movement. The evidence under regulatory review primarily focuses on specific, short-term outcomes in adults.

---

Evidence for Nocturnal Heartburn associated with GERD in Adults

The primary body of research includes studies examining Propulsid in adults, which were reviewed by regulators. These investigations consist of randomized, double-blind, placebo-controlled trials (RCTs). These studies were applied in research contexts involving fluctuating or unstable symptoms of Gastroesophageal Reflux Disease (GERD). Researchers focused on symptom assessment, specifically measuring the frequency and severity of nocturnal heartburn, and this measurement was the main focus of assessment in clinical trials. Studies also monitored physiological strain or stress by looking at objective measurements of the rate of gastric emptying and the pressure of the Lower Esophageal Sphincter (LESP).

Research highlights changes measured during the study period, typically running for 4 to 12 weeks. Studies observed patterns where symptom frequency assessments were reported differently between the group receiving cisapride and the placebo groups. Studies described patterns related to changes in physiological measures, such as assessments of LESP and measurements of stomach emptying rates. However, the findings were mixed when researchers examined outcomes reflecting daily functioning or activity level, such as overall heartburn experience. Research provides insight into short-term changes for nocturnal symptoms, but the long-term effects are not fully established beyond the typical few months of the initial study period.

---

Investigational Studies and Limited Evidence Contexts

Cisapride was also evaluated in research contexts involving other common gastrointestinal issues. Studies explored conditions characterized by functional limitations, such as Nonulcer Dyspepsia (NUD) and Gastroparesis. These studies typically used symptom scales to explore outcomes related to discomfort, bloating, and postprandial fullness for NUD, and studies also monitored objective functional outcomes like the rate of stomach emptying. Findings for conditions like NUD were mixed and showed significant variability across different studies. For patients with gastroparesis, research describes that studies monitored physiological changes, with some reports indicating faster gastric emptying rates; however, evidence remains limited for this complex condition. Studies involving patients with diabetic gastroparesis described changes in gastric emptying rates but did not observe an associated pattern in long-term measures of blood sugar control. The evidence derived from these non-primary contexts is often based on smaller cohorts or older data, and certainty remains low for these specific indications.

Common questions about Propulsid (FAQ)

Q: Is Propulsid (cisapride) still available for prescription?

Propulsid was voluntarily withdrawn from the U.S. and some international markets in 2000 due to reports of serious and potentially fatal heart-related side effects. The product remains restricted and is generally only available through a highly controlled, restricted access protocol for very specific, life-threatening conditions where other treatments have failed.

Q: What serious side effects caused the restrictions on Propulsid?

The primary concern was the potential for Propulsid to cause a specific type of abnormal heart rhythm called QT prolongation, which could lead to ventricular tachycardia, ventricular fibrillation, and sudden death. This risk was particularly noted when used with certain interacting medications.

Q: Can Propulsid be used for routine heartburn or acid reflux?

Due to the significant heart-related risks and restrictions, Propulsid is not indicated or recommended for routine, non-life-threatening conditions such as common heartburn, acid reflux, or non-ulcer dyspepsia. Safer alternatives are available and should be discussed with a healthcare provider.

Q: If I was prescribed Propulsid years ago, should I be concerned?

The long-term effects of past use of Propulsid are generally not a concern. The risks were primarily associated with current use, high doses, use with interacting medications, or in patients with pre-existing heart conditions. If you have any concerns about your medical history, it is recommended to discuss them with a healthcare professional.

Propulsid (cisapride) must be stored under specific conditions defined in regulatory labeling to maintain its stability.

Official Storage Requirements

Requirement	Condition
Temperature	15 –25 C (59 –77 F) (Controlled Room Temperature)
Protection	Tablets must be protected from moisture; 20 mg tablets also from light.
Packaging	Keep the medicine in its original container, tightly closed, away from excess heat.
Child Safety	Must be stored out of the reach and sight of children.

Disposal Instructions

Disposal must adhere to the general guidance for unused medicines, as no drug-specific flushing instructions are provided. The preferred method is using a drug take-back program. If a take-back option is unavailable, the medication should be mixed with an unappealing substance, sealed in a bag or container, and placed in the household trash. Identifying information on the prescription label must be removed or obscured before disposal of the empty packaging.